A Nanoparticle-based Nicotine Vaccine and the Influence of Particle Size on Its Immunogenicity and Efficacy

Overview

Journal Nanomedicine

Publisher Elsevier

Specialties Biomedical Engineering
Biotechnology

Date 2016 Aug 14

PMID 27520729

Citations 25

Authors

Zongmin Zhao

Yun Hu

Reece Hoerle

Meaghan Devine

Michael Raleigh

Paul Pentel

Chenming Zhang

Affiliations

Soon will be listed here.

Abstract

Traditional hapten-protein conjugate nicotine vaccines have shown less than desired immunological efficacy due to their poor recognition and internalization by immune cells. We developed a novel lipid-polymeric hybrid nanoparticle-based nicotine vaccine to enhance the immunogenicity of the conjugate vaccine, and studied the influence of particle size on its immunogenicity and pharmacokinetic efficacy. The results demonstrated that the nanovaccines, regardless of size, could induce a significantly stronger immune response against nicotine compared to the conjugate vaccine. Particularly, a significantly higher anti-nicotine antibody titer was achieved by the 100 compared to the 500nm nanovaccine. In addition, both the 100 and 500nm nanovaccines reduced the distribution of nicotine into the brain significantly. The 100nm nanovaccine exhibited better pharmacokinetic efficacy than the 500nm nanovaccine in the presence of alum adjuvant. These results suggest that a lipid-polymeric nanoparticle-based nicotine vaccine is a promising candidate to treat nicotine dependence.

Citing Articles

Conjugation of Multiple Proteins Onto the Surface of PLGA/Lipid Hybrid Nanoparticles.

Hu H, Zhang C J Biomed Mater Res A. 2024; 113(1):e37807.

PMID: 39420678 PMC: 11669531. DOI: 10.1002/jbm.a.37807.

The immunological and pharmacokinetic evaluation of Lipid-PLGA hybrid nanoparticle-based oxycodone vaccines.

Walter D, Bian Y, Hu H, Hamid F, Rostamizadeh K, Vigliaturo J Biomaterials. 2024; 313:122758.

PMID: 39182328 PMC: 11402561. DOI: 10.1016/j.biomaterials.2024.122758.

Unfolding Protein-Based Hapten Coupling via Thiol-Maleimide Click Chemistry: Enhanced Immunogenicity in Anti-Nicotine Vaccines Based on a Novel Conjugation Method and MPL/QS-21 Adjuvants.

Xu Y, Li H, Meng X, Yang J, Xue Y, Teng C Polymers (Basel). 2024; 16(7).

PMID: 38611189 PMC: 11013800. DOI: 10.3390/polym16070931.

Nano toolbox in immune modulation and nanovaccines.

Azharuddin M, Zhu G, Sengupta A, Hinkula J, Slater N, Patra H Trends Biotechnol. 2022; 40(10):1195-1212.

PMID: 35450779 PMC: 10439010. DOI: 10.1016/j.tibtech.2022.03.011.

Nanoparticle delivery systems for substance use disorder.

Kasina V, Mownn R, Bahal R, Sartor G Neuropsychopharmacology. 2022; 47(8):1431-1439.

PMID: 35351961 PMC: 8960682. DOI: 10.1038/s41386-022-01311-7.

References

Rosalia R, Cruz L, van Duikeren S, Tromp A, Silva A, Jiskoot W . CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials. 2014; 40:88-97. DOI: 10.1016/j.biomaterials.2014.10.053. View

Zheng H, Hu Y, Huang W, de Villiers S, Pentel P, Zhang J . Negatively Charged Carbon Nanohorn Supported Cationic Liposome Nanoparticles: A Novel Delivery Vehicle for Anti-Nicotine Vaccine. J Biomed Nanotechnol. 2015; 11(12):2197-210. PMC: 5344192. DOI: 10.1166/jbn.2015.2156. View

Carpenter M, Jardin B, Burris J, Mathew A, Schnoll R, Rigotti N . Clinical strategies to enhance the efficacy of nicotine replacement therapy for smoking cessation: a review of the literature. Drugs. 2013; 73(5):407-26. PMC: 3662024. DOI: 10.1007/s40265-013-0038-y. View

Gebril A, Lamprou D, Alsaadi M, Stimson W, Mullen A, Ferro V . Assessment of the antigen-specific antibody response induced by mucosal administration of a GnRH conjugate entrapped in lipid nanoparticles. Nanomedicine. 2013; 10(5):971-9. DOI: 10.1016/j.nano.2013.12.005. View

Pentel P, Lesage M . New directions in nicotine vaccine design and use. Adv Pharmacol. 2014; 69:553-80. PMC: 4047682. DOI: 10.1016/B978-0-12-420118-7.00014-7. View

Chua B, Sekiya T, Al Kobaisi M, Short K, Mainwaring D, Jackson D . A single dose biodegradable vaccine depot that induces persistently high levels of antibody over a year. Biomaterials. 2015; 53:50-7. DOI: 10.1016/j.biomaterials.2015.02.066. View

de Villiers S, Cornish K, Troska A, Pravetoni M, Pentel P . Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum. Vaccine. 2013; 31(52):6185-93. PMC: 4019346. DOI: 10.1016/j.vaccine.2013.10.051. View

McCluskie M, Thorn J, Mehelic P, Kolhe P, Bhattacharya K, Finneman J . Molecular attributes of conjugate antigen influence function of antibodies induced by anti-nicotine vaccine in mice and non-human primates. Int Immunopharmacol. 2015; 25(2):518-27. DOI: 10.1016/j.intimp.2015.02.030. View

Hu Y, Ehrich M, Fuhrman K, Zhang C . In vitro performance of lipid-PLGA hybrid nanoparticles as an antigen delivery system: lipid composition matters. Nanoscale Res Lett. 2014; 9(1):434. PMC: 4154617. DOI: 10.1186/1556-276X-9-434. View

10.

Lesage M, Keyler D, Pentel P . Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. AAPS J. 2006; 8(1):E65-75. PMC: 3889506. DOI: 10.1208/aapsj080108. View

11.

Cornuz J, Zwahlen S, Jungi W, Osterwalder J, Klingler K, van Melle G . A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One. 2008; 3(6):e2547. PMC: 2432028. DOI: 10.1371/journal.pone.0002547. View

12.

Shen X, Orson F, Kosten T . Vaccines against drug abuse. Clin Pharmacol Ther. 2011; 91(1):60-70. PMC: 3345810. DOI: 10.1038/clpt.2011.281. View

13.

Noe S, Green M, HogenEsch H, Hem S . Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response. Vaccine. 2010; 28(20):3588-94. DOI: 10.1016/j.vaccine.2010.02.085. View

14.

Cheow W, Hadinoto K . Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles. Colloids Surf B Biointerfaces. 2011; 85(2):214-20. DOI: 10.1016/j.colsurfb.2011.02.033. View

15.

Hatsukami D, Jorenby D, Gonzales D, Rigotti N, Glover E, Oncken C . Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther. 2011; 89(3):392-9. PMC: 4106715. DOI: 10.1038/clpt.2010.317. View

16.

Benowitz N . Nicotine addiction. N Engl J Med. 2010; 362(24):2295-303. PMC: 2928221. DOI: 10.1056/NEJMra0809890. View

17.

Pravetoni M, Keyler D, Pidaparthi R, Carroll F, Runyon S, Murtaugh M . Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochem Pharmacol. 2011; 83(4):543-50. PMC: 3259188. DOI: 10.1016/j.bcp.2011.11.004. View

18.

Harris J, Markl J . Keyhole limpet hemocyanin (KLH): a biomedical review. Micron. 1999; 30(6):597-623. DOI: 10.1016/s0968-4328(99)00036-0. View

19.

Hu Y, Hoerle R, Ehrich M, Zhang C . Engineering the lipid layer of lipid-PLGA hybrid nanoparticles for enhanced in vitro cellular uptake and improved stability. Acta Biomater. 2015; 28:149-159. PMC: 4648676. DOI: 10.1016/j.actbio.2015.09.032. View

20.

Doll T, Neef T, Duong N, Lanar D, Ringler P, Muller S . Optimizing the design of protein nanoparticles as carriers for vaccine applications. Nanomedicine. 2015; 11(7):1705-13. PMC: 4587294. DOI: 10.1016/j.nano.2015.05.003. View